Professor C.W. Howden, Editor

Professor Howden is a consultant for Allakos, EndoStim, Ironwood, Phathom Pharmaceuticals and RedHill Biopharma. He owns stock in Antibe Therapeutics. He is a member of speakers’ bureaus for Alnylam, Genzyme/Sanofi and RedHill Biopharma

Professor R. Loomba, Editor

Professor Loomba serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. In addition, his institution received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc. He receives funding support from NCATS (5UL1TR001442), NIDDK (U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318, P30DK120515), NHLBI (P01HL147835) and NIAAA (U01AA029019).

Professor A. C. Ford, Associate Editor

Professor Ford has received grant/research support from Almirall, Dr. Falk, GE Healthcare and Tillotts Pharma, and acted as a consultant/speaker for Almirall, Dr. Falk, GE Healthcare, Ipsen Pharma SPA, Mayoly-Spindler, MSD, Norgine, Novartis, Shire Pharmaceuticals and Takeda Pharmaceuticals.

Professor G. M. Dusheiko, Associate Editor

Professor Dusheiko serves on independent data safety monitoring boards for Aligos, Arbutus, Enanta, Glaxo Smith Kline, Janssen and Myr. In the past 2 years, he has received honoraria from Arbutus, Antios, Aligos, Cepheid, Gilead Sciences and Shionogi. He serves as an advisor to the National Medical Research Council, Singapore, the TherVacB Consortium (European Horizon Grant) and the A-Tango Consortium (EUH2020 grant).

Professor P. R. Gibson, Associate Editor

Professor Gibson has served as a consultant or advisory board member for Anatara, Atmo Biosciences, Comvita, Falk Pharma, Immunic Therapeutics, Novoviah, Novozymes and Takeda. He has received research grants for investigator-driven studies from Atmo Biosciences. He holds shares in Atmo Biosciences. His department financially benefits from the sales of a digital application, booklets and online courses on the FODMAP diet.

Professor G. L.-H. Wong, Associate Editor

Professor Wong has served as an advisory committee member for Gilead Sciences and Janssen, and as a speaker for Abbott, Abbvie, Ascletis Pharmaceuticals, Bristol-Myers Squibb, Echosens, Gilead Sciences, Janssen and Roche.

Dr N. A. Kennedy, Associate Editor

Dr Kennedy has served as a speaker and/or advisory board member for AbbVie, Allergan, Falk, Ferring, Galapagos, Janssen, Mylan, Pharmacosmos, Sandoz, Takeda and Tillotts. He has had support to attend meetings from AbbVie, Falk, Janssen and Norgine. His department has received research funding from AbbVie, Biogen, Celgene, Celtrion, Galapagos, MSD, Napp, Pfizer, Pharmacosmos, Roche and Takeda.

Professor R. B. Gearry, Associate Editor

Professor Gearry is, or has been, a member of advisory boards for AbbVie, Janssen, Schering-Plough, Zespri, Baxter and Celltrion. He has received honoraria or travel grants from AbbVie, Janssen, Schering Plough, Zespri, Ferring and Celltrion. He has received research grants for investigator-initiated studies from AbbVie and Zespri.

Professor G. M. Hirschfield, Associate Editor

Professor Hirschfield has consulted for Cymabay, Genfit, Gilead, GSK, Intercept Pharma, Pliant, Mirum, Morphogen and Roche. He has been a speaker for Falk Pharma and Intercept Pharma. He has received grant support/unrestricted educational support from Intercept Pharma. He has been a study investigator for Cymabay, Enanta, Falk Pharma, Genfit, Genkyotec, Gilead, GSK, HighTide, Intercept Pharma and Novartis.

Professor S. D. Ryder, Associate Editor

Professor Ryder has acted as a clinical advisor to Abbvie, Gilead Sciences and Intercept Pharmaceuticals, and has undertaken paid speaking engagements for them. He has received research funding from Gilead Sciences. He is the Medical Advisor for The British Liver Trust.

Dr C. H. Seow, Associate Editor

Dr Seow is a member of advisory boards for Abbvie, Amgen, Ferring, Fresenius Kabi, Janssen, Pfizer, Pharmascience, Sandoz, Shire and Takeda and has been a speaker for Abbvie, Ferring, Janssen, Pfizer, Pharmascience, Shire and Takeda. She receives research funding from Takeda.

Dr M. D. Burkitt, Reviews Editor

Dr Burkitt has received support to attend meetings from Allergan and Janssen and has acted as a speaker for Takeda and Janssen.

Professor R. E. Pounder, Founding Editor 1987-2017; Emeritus Editor and Advisor 2018-present

None to declare.

CW Howden 教授，编辑

Howden 教授是 Allakos、EndoStim、Ironwood、Phathom Pharmaceuticals 和 RedHill Biopharma 的顾问。他拥有 Antibe Therapeutics 的股票。他是 Alnylam、Genzyme/Sanofi 和 RedHill Biopharma 发言人局的成员

R. Loomba 教授，编辑

Loomba 教授担任 Aardvark Therapeutics、Altimmune、Anylam/Regeneron、Amgen、Arrowhead Pharmaceuticals、AstraZeneca、Bristol-Myer Squibb、CohBar、Eli Lilly、Galmed、Gilead、Glympse bio、Hightide、Inipharma、Intercept、Inventiva、Ionis、 Janssen Inc.、Madrigal、Metacrine, Inc.、NGM Biopharmaceuticals、诺华、诺和诺德、默克、辉瑞、Sagimet、Theratechnologies、89 bio、Terns Pharmaceuticals 和 Viking Therapeutics。此外，他的机构还获得了 Arrowhead Pharmaceuticals、Astrazeneca、Boehringer-Ingelheim、Bristol-Myers Squibb、Eli Lilly、Galectin Therapeutics、Galmed Pharmaceuticals、Gilead、Intercept、Hanmi、Intercept、Inventiva、Ionis、Janssen、Madrigal Pharmaceuticals、Merck 的研究资助, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes 和 Terns Pharmaceuticals。

AC Ford教授，副主编

Ford 教授获得了 Almirall、Falk 博士、GE Healthcare 和 Tillotts Pharma 的资助/研究支持，并担任 Almirall、Falk 博士、GE Healthcare、Ipsen Pharma SPA、Mayoly-Spindler、MSD、Norgine、诺华、夏尔制药和武田制药。

GM Dusheiko教授，副主编

Dusheiko 教授在 Aligos、Arbutus、Enanta、Glaxo Smith Kline、Janssen 和 Myr 的独立数据安全监控委员会任职。在过去的 2 年里，他收到了来自 Arbutus、Antios、Aligos、Cepheid、Gilead Sciences 和 Shionogi 的酬金。他担任新加坡国家医学研究委员会、TherVacB 联盟（欧洲地平线资助）和 A-Tango 联盟（EUH2020 资助）的顾问。

PR Gibson 教授，副主编

Gibson 教授曾担任 Anatara、Atmo Biosciences、Comvita、Falk Pharma、Immunic Therapeutics、Novoviah、Novozymes 和 Takeda 的顾问或顾问委员会成员。他获得了来自 Atmo Biosciences 的研究人员驱动研究的研究资助。他持有 Atmo Biosciences 的股份。他的部门从 FODMAP 饮食的数字应用程序、小册子和在线课程的销售中受益。

GL-H教授。黄，副主编

黄教授曾担任 Gilead Sciences 和 Janssen 的顾问委员会成员，并担任 Abbott、Abbvie、Ascletis Pharmaceuticals、Bristol-Myers Squibb、Echosens、Gilead Sciences、Janssen 和 Roche 的发言人。

NA Kennedy 博士，副主编

Kennedy 博士曾担任 AbbVie、Allergan、Falk、Ferring、Galapagos、Janssen、Mylan、Pharmacosmos、Sandoz、Takeda 和 Tillotts 的发言人和/或顾问委员会成员。他得到了来自 AbbVie、Falk、Janssen 和 Norgine 的支持参加会议。他的部门获得了来自 AbbVie、Biogen、Celgene、Celtrion、Galapagos、MSD、Napp、辉瑞、Pharmacosmos、罗氏和武田的研究资助。

RB Gearry 教授，副主编

Gearry 教授是或曾经是 AbbVie、Janssen、Schering-Plough、Zespri、Baxter 和 Celltrion 的顾问委员会成员。他获得了艾伯维、杨森、先灵葆雅、佳沛、辉凌和 Celltrion 的酬金或旅行补助金。他获得了来自 AbbVie 和 Zespri 的研究人员发起的研究资助。

GM Hirschfield教授，副主编

Hirschfield 教授曾为 Cymabay、Genfit、Gilead、GSK、Intercept Pharma、Pliant、Mirum、Morphogen 和 Roche 提供咨询。他一直是 Falk Pharma 和 Intercept Pharma 的发言人。他获得了 Intercept Pharma 的赠款支持/不受限制的教育支持。他曾担任 Cymabay、Enanta、Falk Pharma、Genfit、Genkyotec、Gilead、GSK、HighTide、Intercept Pharma 和 Novartis 的研究调查员。

SD Ryder 教授，副主编

Ryder 教授曾担任 Abbvie、Gilead Sciences 和 Intercept Pharmaceuticals 的临床顾问，并为他们进行有偿演讲活动。他获得了吉利德科学的研究经费。他是英国肝脏信托基金的医疗顾问。

CH Seow 博士，副主编

Seow 博士是 Abbvie、Amgen、Ferring、Fresenius Kabi、Janssen、Pfizer、Pharmascience、Sandoz、Shire 和 Takeda 的顾问委员会成员，并曾是 Abbvie、Ferring、Janssen、Pfizer、Pharmascience、Shire 和 Takeda 的发言人。她从武田获得研究经费。

MD Burkitt 博士，评论编辑

Burkitt 博士获得了艾尔建 (Allergan) 和杨森 (Allergan) 和杨森 (Janssen) 会议的支持，并担任武田 (Takeda) 和杨森 (Janssen) 的发言人。

RE Pounder教授，1987-2017创始编辑；2018 年至今名誉编辑和顾问

无需申报。